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ABSTRACT
Metformin is a widely used agent for the treatment of diabetes and infertility, 
however, it has been found to have anti-cancer effects in a variety of malignancies 
including high grade serous ovarian cancer (HGSC). Studies describing the mechanisms 
by which metformin affects HGSC are ongoing, but detailed analysis of its effect on 
the cellular metabolism of both HGSC cells and their precursor, normal fallopian 
tube secretory epithelial cells (FTSECs), is lacking. We addressed the effects of 
metformin and the more potent biguanide, phenformin, on HGSC cell lines and normal 
immortalized FTSECs. Cell proliferation assays identified that FTSECs and a subset of 
HGSC cell lines are relatively resistant to the anti-proliferative effects of metformin. 
Bioenergetic and metabolomic analyses were used to metabolically differentiate the 
metformin-sensitive and metformin-resistant cell lines. Bioenergetically, biguanides 
elicited a significant decrease in mitochondrial respiration in all HGSC cells and FTSECs. 
However, biguanides had a greater effect on mitochondrial respiration in metformin 
sensitive cells. Metabolomic analysis revealed that metformin and phenformin 
generally induce similar changes in metabolic profiles. Biguanide treatment led to 
a significant increase in NADH in FTSECs and HGSC cells. Interestingly, biguanide 
treatment induced changes in the levels of mitochondrial shuttle metabolites, 
glycerol-3-phopshate (G3P) and aspartate, specifically in HGSC cell lines and not in 
FTSECs. Greater alterations in G3P or aspartate levels were also found in metformin 
sensitive cells relative to metformin resistant cells. These data identify bioenergetic 
and HGSC-specific metabolic effects that correlate with metformin sensitivity and 
novel metabolic avenues for possible therapeutic intervention.
INTRODUCTION
Ovarian cancer remains the leading cause of 
gynecologic cancer-related death in women despite 
widespread efforts to improve surgical procedures and 
therapeutic targets [1]. In 2015, 21,290 new ovarian 
cancer diagnoses were made in the United States, and 
>66% (14,180) of these women died of the disease [2]. 
High grade serous carcinoma (HGSC) accounts for over 
half of ovarian cancers and carries the worst overall 
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prognosis [1]. Standard treatment for ovarian cancer 
involves surgical debulking with the goal of no gross 
residual disease, followed by combination platinum and 
taxane chemotherapy. Despite advances there have been 
only modest improvements in the overall 5- and 10-
year relative survival rates which remain 46% and 35%, 
respectively [1]. Repurposing low-toxicity drugs may help 
improve the progression free and overall survival rates [1]. 
Also, understanding the mechanism of how low toxicity 
drugs affect cancer cells may reveal additional therapeutic 
targets.
Metformin, a biguanide drug with a low toxicity 
profile, has been widely used to treat diabetes and fertility 
[3, 4]. In 2005, Evans et al reported a reduced incidence 
of cancer in diabetic patients receiving metformin, which 
led to recognition of the drug in cancer-related research 
[4]. Another large prospective study found that diabetic 
women treated with metformin have a lower risk of dying 
of most invasive cancers compared to non-metformin 
users [5]. Metformin and phenformin, two biguanide 
drugs traditionally used to treat diabetes, have now been 
associated with improved survival rates in many different 
cancer types including non-small cell lung, breast and 
ovarian cancers [6–8]. Due to safety concerns, phenformin 
has been removed from the pharmaceutical market for use 
in humans [9]. However, recent studies have shown that 
phenformin treatment may have some utility in treating 
cancer with a shorter treatment schedule that reduces the 
risk of severe side effects [6].
As anti-diabetic medications, biguanides primarily 
act as an insulin sensitizers, decrease blood glucose 
levels, and reduce gluconeogenesis in the liver [10]. 
Both increased levels of insulin and glucose have been 
associated with tumor growth and poor overall prognosis 
in different cancer types [10]. Therefore, the ability of 
biguanides to lower both glucose and insulin levels may 
indirectly contribute to its anti-tumor effects. In addition 
to these indirect effects, biguanides are also posited to 
directly affect cancer cell proliferation via inhibition of 
Complex I within the electron transport chain [11]. Indeed, 
it was recently found that metformin accumulates in 
tumors and induce metabolic changes similar to that seen 
in vitro [12]. The bioenergetic stress induced by metformin 
inhibits proliferation and was largely thought to be mTOR 
dependent [13, 14]. However, metformin inhibition of 
mTOR has been shown to vary between different studies 
and cell types, with no correlation to its anti-proliferative 
effects [12, 15].
Preclinical studies focusing on the effect of 
metformin on HGSC have identified its anti-proliferative 
effects [8, 12, 16]. These data and epidemiological 
evidence have led to clinical trials assessing the use of 
metformin in both neoadjuvant and post-surgical settings 
for HGSC [12, 17]. However, a molecular characterization 
of cell lines widely used to study HGSC revealed that 
they are, in fact, not likely to represent the disease [18]. 
Also, growing evidence has pointed to the fallopian tube 
secretory epithelial cells (FTSEC) as the origin of HGSC 
[19]. FTSECs have not been metabolically characterized, 
and their response to biguanides are unknown. Extensive 
metabolic characterization of HGSC cells has also not 
been reported. Therefore, to assess the metabolic and 
potential anti-proliferative effect of biguanides in HGSC, 
we performed bioenergetic and metabolomic analysis on 
a panel of clinically relevant HGSC lines and normal cell 
of origin controls. We find that a subset of HGSC cell lines 
as well as normal FTSECs are relatively resistant to the 
anti-proliferative effects of metformin. Also, these effects 
do not correlate with the ability of metformin to inhibit 
AMPK/mTOR signaling. Bioenergetic analysis revealed 
that metformin sensitivity largely correlated with a greater 
inhibition of oxygen consumption rate. Also, metabolomic 
analysis identified specific alterations in HGSC cells 
versus normal FTSECs that also correlate with metformin 
sensitivity.
RESULTS
Biguanides inhibit HGSC cell proliferation
We examined the effect of metformin and 
phenformin on normal FTSEC and HGSC proliferation 
in 2-D growth conditions. We analyzed a panel of HGSC 
cell lines (FUOV1, OV90, OVCAR4, OVCAR433, 
and TYKNU), which were previously characterized as 
suitable HGSC models given their genetic makeup (i.e. 
TP53 mutation, copy-number profile, and low frequency 
of non-synonymous mutations in protein-coding genes) 
[19]. Normal TERT-immortalized fallopian tube non-
ciliated epithelium cell lines, FNE1 and FNE2, were used 
as normal controls [20]. Normal FTSECs and HGSCs 
were treated with either metformin, phenformin, or vehicle 
control (Figure 1). In FTSECs, metformin treatment led to 
a modest growth inhibition (~30-40%), while phenformin 
completely inhibited cell proliferation (Figure 1A & 1D). 
In HGSCs, phenformin also significantly inhibited cell 
proliferation (Figures 1B & 1C). However, metformin 
treatment of HGSC cell lines revealed two subgroups; 
Metformin-sensitive (TYKNU, OV90, and OVCAR433) 
and metformin-resistant (OVCAR4 and FUOV1) (Figure 
2B–2D). Metformin completely inhibited the cell 
proliferation of metformin-sensitive cells (Figure 1B & 
1D), while metformin-resistant cells responded similarly 
to normal FTSECs, with OVCAR4 being slightly more 
sensitive (Figure 1C & 1D).
We also assessed the effect of metformin and 
phenformin on anchorage independent 3D growth. Cells 
were grown in ultra-low attachment plates for 24 hours to 
form cellular aggregates and then treated with metformin, 
phenformin, or vehicle. As expected, FNE1 and FNE2 
were unable to survive anchorage-independent conditions 
(Figure 2A). However, all HGSC cell lines formed 
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Figure 1: The effects of biguanides on 2-D cell proliferation of HGSC and normal FTSEC cell lines. (A) Normal FTSECs, 
(B) metformin sensitive and (C) metformin resistant cells grown in 2-D were treated with the indicated doses of metformin, phenformin, or 
vehicle control at 24 h for 5 days. Cell proliferation was assessed at indicated time points by Celltiter Glo. Proliferation is displayed relative 
to vehicle control at 24h. (D) Metformin efficacy calculated based on metformin treatment relative to control after 5 days of treatment. 
*denotes significant inhibition relative to control treatment (p-value <.01).
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Figure 2: The effects of biguanides on 3-D cell proliferation of HGSC and normal FTSEC cell lines. (A) Normal FTSECs, 
(B) metformin sensitive and (C) relatively metformin resistant cells grown in ultra-low attachment 3D conditions. Cell proliferation was 
assessed at indicated time points by Celltiter Glo 3D. Proliferation is displayed relative to vehicle control at 24h. (D) Metformin efficacy 
calculated based on metformin treatment divided by control treatment at 5 days of treatment. (E) Proliferation at 6 days relative to 24 h. (F) 
Plot of metformin efficacy versus cell proliferation rates. Dotted red line is best-fit trend line of all data points and statistically significant 
to be non-zero (p-value <0.01). *denotes significant inhibition relative to control treatment (p-value <0.01).
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stable cell aggregates and continued to survive after 6 
days (Figure 2B & 2C). Cells were less proliferative in 
3D conditions compared to 2D conditions (Figures 1 & 
2). Generally, cell lines that were highly proliferative 
in 2D (TYKNU, OV90, and OV433) were also more 
proliferative than other cells in 3D (Figure 1 & 2). The 
effects of metformin in 3D were similar to those observed 
in 2D; the growth of TYKNU, OV90, and OVCAR433 
was significantly inhibited by metformin, whereby 
OVCAR4 and FUOV1 were not (Figure 2B–2D). We 
noticed that the 3D growth of metformin resistant cells 
was significantly slower than that of the metformin 
sensitive cells (Figure 2E). Indeed, there was a statistically 
significant (p-value =.0037) inverse relationship between 
metformin resistance and 3D cell proliferation rate (Figure 
2F). These data indicate that normal FTSECs and a subset 
of HGSC cell lines are relatively metformin resistant.
The effect of metformin on proliferation does not 
correlate with phospho-S6K levels
The effect of biguanide treatment on proliferation 
in other cell types has been primarily described through 
inhibition of mTOR activation via the upregulation of 
AMPK activity or REDD1, both well-established mTOR 
inhibitors [6, 13, 14]. To identify possible differences 
between metformin-resistant and metformin-sensitive 
cells, we examined the effects of biguanides on the 
mTOR signaling pathway in FTSEC and HGSC cells. 
Both biguanides induced AMPK Thr172 phosphorylation 
(pAMPK) only in the metformin-resistant lines (OVCAR4 
and FUOV1) (Figure 3). Phenformin, but not metformin, 
also induced pAMPK in FNE1 (Figure 3). We further 
performed time course experiments addressing the effect 
of metformin and a potent inducer of AMPK, AICAR, in 
the metformin-sensitive, OV90, and metformin-resistant, 
FUOV1, cell lines. Metformin was able to induce a 
subtle increase in pAMPK in OV90 after 6 hours which 
decreased significantly by 48 h (Supplementary Figure 
1A). This is juxtaposed to the dramatic and sustained 
increase of pAMPK in FUOV1 cells (Supplementary 
Figure 1A). AICAR was able to induce phospho-AMPK 
levels in both cell lines, however to a much lesser 
extent in OV90 (Supplementary Figure 1A). Metformin 
sensitivity also did not correlate with the expression 
of the upstream modulator of AMPK activity, LKB1, 
nor the expression of the metformin transporter, OCT1 
(Supplementary Figure 1B&1C). Western blot analysis 
of REDD1 found that both biguanides induced REDD1 
protein levels in all HGSC cells, while only phenformin 
treatment led to elevated levels of REDD1 in normal 
FTSEC cells (Figure 3). We determined whether REDD1 
was also transcriptionally upregulated by performing qRT-
PCR analysis. Indeed, both biguanides induced similar 
levels of REDD1 mRNA in HGSC cells but not in normal 
FTSECs (Supplementary Figure 2). We then assessed 
mTOR activity via the phosphorylation status of the 
mTOR downstream target, S6 kinase (S6K), by western 
blot. Phenformin significantly decreased phospho-S6 
kinase (pS6K) levels in all cell lines, indicating mTOR 
inhibition (Figure 3). In contrast, metformin decreased 
pS6K levels in only two cell lines, TYKNU (metformin-
sensitive) and FUOV1 (metformin-resistant) (Figure 3). 
Therefore, these data suggest that phenformin is a more 
Figure 3: The effects of biguanides on mTOR signaling in HGSC and normal FTSEC cell lines. Cell lines were treated 
with metformin (10 mM), phenformin (1 mM), or vehicle control for 24 hours. Western blot analysis of phospho-AMPK (T172), AMPK, 
phospho-S6K (T389), S6K, REDD1, and β-actin as a loading control.
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potent inhibitor of mTOR activity than metformin, even 
at doses where metformin has anti-proliferative effects. 
Together, these data are in line with other studies that 
suggest upregulation of pAMPK, REDD1, and inhibition 
of mTOR activity does not correlate with metformin 
sensitivity in cancer cell lines [12, 15]. It also indicates 
that the anti-proliferative effects of metformin may be 
at least partially attributable to mechanisms other than 
mTOR inhibition.
HGSC cell lines have altered bioenergetic 
profiles compared to normal FTSECs
Since the effects of metformin could not be fully 
explained by mTOR inhibition, we sought to characterize 
the metabolic and bioenergetic effects of biguanide 
treatment. We initially profiled the baseline bioenergetic 
activities of FTSECs and HGSC cell lines utilizing the 
Seahorse bioanalyzer to assess oxygen consumption 
rate (OCR), a key indicator of mitochondrial activity 
and cellular respiration, as well as the extracellular 
acidification rate (ECAR), an indicator of glycolysis. 
Analysis of the baseline OCR revealed that HGSC cell 
lines display a significantly increased OCR relative to 
normal cells (Figure 4A). In addition, most HGSC cell 
lines, except OVCAR4 and OV90, have an increased 
baseline ECAR relative to normal cells (Figure 4B). 
These data imply that HGSC cells have elevated cellular 
respiration and increased glycolysis as compared to their 
cell of origin counterparts.
Since HGSC cells displayed significantly elevated 
OCR and ECAR, we determined whether these cells were 
functioning at their maximal respiratory and glycolytic 
capacities. FCCP, a mitochondrial uncoupler, induces 
maximal respiration by transporting protons across the 
mitochondrial membrane leading to depolarization of the 
membrane potential and rapid consumption of O2. This 
maximal OCR is used in conjunction with basal OCR 
to calculate spare respiratory capacity. FNE1 and FNE2 
mitochondria were functioning at 80% and 67% capacity 
with 20% and 37% spare respiratory capacity, respectively 
(Figure 4C). While a few HGSC cell lines (FUOV1, 
OVCAR433, and TYKNU) were functioning at near 
maximal capacity (>90% capacity, <10% spare respiratory 
capacity), other HGSC cell lines (OV90, OVCAR4) were 
functioning at significantly lower (<70% capacity, >30% 
spare respiratory capacity), or similar capacities relative 
to normal (Figure 4C). Therefore, no general trend in 
spare respiratory capacity could be identified between 
metformin-resistant cells, metformin-sensitive cells, and 
normal controls. To calculate maximal glycolytic capacity, 
oligomycin, an ATP synthase inhibitor, was used to induce 
a bioenergetic shift towards glycolysis (maximal ECAR). 
Similar to spare respiratory capacity, there were no 
significant differences between HGSC and control cells in 
spare glycolytic capacities (Figure 4D).
We further assessed other facets of mitochondrial 
function including the percentage of respiration devoted 
to ATP production (ATP-coupled), proton leak (ATP-
uncoupled), and non-mitochondrial respiration. OCR 
measurements during sequential treatment of cell lines 
with oligomycin (ATP synthase inhibitor) and rotenone/
myxothiazol (Complex I and III inhibitors, respectively) 
allow for these parameters to be defined. Normal cell 
lines, FNE1 and FNE2, have greater than 60% of their 
total respiration dedicated to ATP synthesis (Figure 
4E). However, all HGSC cell lines tested demonstrate 
significantly less ATP-coupled OCR than controls with 
the majority of their respiration being allocated towards 
uncoupled and non-mitochondrial respiration (Figure 
4E). This phenomenon of elevated non-ATP-coupled 
respiration in cancer versus normal cells has also been 
observed in breast cancer [21]. Altogether these data 
suggest that HGSC cells are more bioenergetic, while 
contributing a smaller fraction of their total respiration 
towards ATP-synthesis compared to normal cells.
Biguanides significantly inhibit oxygen 
consumption while increasing glycolysis in both 
normal FTSECs and HGSC cells that can be 
exploited in low glucose conditions
To assess the effects of metformin and phenformin 
on mitochondrial function, cell lines were incubated 
for 24 hours with either metformin, phenformin, or 
vehicle control prior to Seahorse bioanalysis. Treatment 
with metformin or phenformin significantly decreased 
respiration (>70% of control OCR) in both HGSC and 
normal cells at similar levels. However, the metformin-
resistant cells (OVCAR4 and FUOV1), still had a 
significantly higher OCR (>10%) than the metformin-
sensitive cells (<10%) (Figure 5A). This implies that 
oxidative phosphorylation is less inhibited in metformin-
resistant cells as compared to metformin-sensitive cells. 
Therefore, metformin and phenformin decrease overall 
oxygen consumption and utilization for ATP-synthesis. 
Biguanides are also more potent in affecting these 
processes in metformin-sensitive cells versus metformin-
resistant cells.
Previous studies have shown that metformin 
inhibition of oxygen consumption leads to a subsequent 
compensatory increase in aerobic glycolysis to compensate 
for the energy deficit in some cell lines [22, 23]. Therefore, 
we examined the effect of metformin and phenformin on 
the ECAR of HGSC and normal cells. Both FNE1 and 
FNE2 had significant ECAR increases upon treatment 
of metformin or phenformin relative to control (Figure 
5B). Most HGSC cell lines also had elevated ECAR 
upon metformin treatment except FUOV1 (Figure 5B). 
Similarly, phenformin treatment increased ECAR in most 
HGSC cell lines except TYKNU and FUOV1 (Figure 
5B). These data confirm previous reports that metformin 
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Figure 4: Bioenergetic analysis of HGSC and normal FTSEC cell lines. (A-E) Oxygen Consumption Rate (OCR) (A, C, 
E) and Extracellular Acidification Rate (ECAR) (B & D) measurements were obtained using an extracellular flux analyzer (Seahorse 
Bioscience). Basal OCR (A) and ECAR (B) rates were obtained prior to addition of Oligomycin A to derive Spare Glycolytic Capacity 
(D) and ATP-coupled OCR (E), and FCCP to uncouple mitochondria for maximal OCR. (C) Spare respiratory capacity was calculated by 
taking the difference between the maximal OCR and basal OCR. Percentages are relative to maximal respiration. (D) Spare Glycolytic 
Capacity was derived by taking the difference between maximal ECAR and basal ECAR. Percentages are relative to maximal ECAR. (E) 
Non-mitochondrial respiration was calculated as the residual OCR after treatment with Rotenone/myxothiazol that inhibits Complex I. 
Uncoupled mitochondrial respiration was calculated as the difference between OCR following Oligomycin A treatment and OCR following 
Rotenone/myxothiazol treatment. All three values are shown as percentages relative to baseline OCR.
Oncotarget4051www.impactjournals.com/oncotarget
Figure 5: The effects of biguanides on the bioenergetics profiles of HGSC and normal FTSEC cell lines. (A and B) 
Cells were treated with Metformin (10 mM), Phenformin (1 mM), or control vehicle for 24 hours prior to analysis by the extracellular flux 
analyzer. (A) Basal OCR relative to control treated cells. * denotes p-value < 0.05 as determined by Tukey’s multiple comparison test. (B) 
Basal ECAR relative to control treated cells. Dotted line indicates the level of a statistically significant change in ECAR (p-value < 0.01).
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and phenformin generally inhibit oxygen consumption, 
but the induction of aerobic glycolysis is governed by 
other factors [22, 23]. Also, under these conditions, 
these bioenergetic effects do not discriminate between 
metformin-sensitive and metformin-resistant cells.
A previous study in ovarian cancer indicated that 
metformin resistance can be overcome by reducing 
glucose concentration, thereby demonstrating the 
inhibitory effect of hyperglycemia on the actions of 
metformin [16]. To address whether glucose served 
as a protective molecule in metformin resistant cells, 
we cultured FUOV1 and OVCAR4 cells in media with 
standard (10 mM) or low (0.1 mM) glucose concentrations 
and treated cells with metformin, phenformin, or control. 
There was no significant difference in cell proliferation 
between untreated glucose and low glucose media after 
6 days (Figure 6A & 6B). However, metformin and 
phenformin treatment significantly inhibited proliferation 
in both cell lines under low glucose conditions compared 
to standard media (Figure 6A & 6B). These data further 
support the previous study that adequate levels of glucose 
are required for biguanide resistant cells to survive.
Metabolomic analysis of metformin and 
phenformin treatment reveals cancer cell specific 
metabolite fluctuations
Due to the significant effect of biguanides on 
mitochondrial function, we were interested in examining 
the effect of biguanides on central carbon metabolism. 
We performed metabolomic analysis on both normal 
FTSECs and all HGSC cell lines (Figure 7, Supplementary 
Figure 3, Supplementary Table 1) Similar to a previous 
study, metformin and phenformin generally induce similar 
metabolic changes in all cell lines tested (Figure 7A, 
Supplementary Figure 3, Supplementary Table 1) [7]. 
Treatment with either molecule induced significantly 
elevated levels of NADH relative to controls in both 
HGSC and normal FTSEC cells, consistent with Complex 
I inhibition by biguanides (Figure 7A, Supplementary 
Figure 3, Supplementary Table 1). In general, biguanide 
treatment of most cell lines including FNE2 cells also 
resulted in the depletion of tricarboxylic acid (TCA) cycle 
intermediates citrate and α-ketoglutarate (Supplementary 
Figure 3 and Supplementary Table 1). Treatment with 
biguanides also caused variable depletion of nucleotide 
triphosphates between cell lines depending on the specific 
treatment. Treatment with phenformin caused relative 
depletion of adenosine triphosphate (ATP), cytidine 
triphosphate (CTP), and uridine triphosphate (UTP) 
in OVCAR433 and TYKNU, but not of other NTPs in 
FUOV1 or OV90. Treatment with metformin caused 
depletion of CTP specifically in FNE2 and FUOV1, 
as well as depletion of UTP in OV90, OVCAR44, and 
TYKNU. Neither treatment caused a significant depletion 
of guanosine triphosphate (GTP) in any of the cell lines 
studied (Supplementary Figure 3 and Supplementary Table 
1). The only metabolite specifically and significantly 
altered in metformin-sensitive cells versus metformin-
resistant cells was the nucleoside deoxyuridine 
(Supplementary Figure 4). Interestingly, we identified 
biguanide-induced alterations that were particular to all 
HGSC cells tested and not normal FTSECs. Specifically, 
in HGSC cells, metformin and phenformin treatment 
caused a significant elevation in glycerol-3-phosphate 
(G3P) and a decrease in aspartate levels relative to 
controls (Figure 7A&7B). Interestingly, the metformin-
sensitive cell lines generally displayed greater effects on 
either G3P accumulation or aspartate depletion than the 
metformin-resistant cell lines, especially OVCAR433 
(Figure 7A&7B). G3P is primarily involved in the 
glycerol-phosphate shuttle, which in addition to the 
malate-aspartate shuttle, allows the movement of electrons 
from cytosolic NADH to the mitochondria for entry into 
the electron transport chain (Figure 8A&8B) [24]. The 
metabolite data suggests that the glycerol-phosphate 
and malate-aspartate shuttle are perturbed by biguanides 
thereby leading to an accumulation of G3P and depletion 
of aspartate. Given that this effect does not occur in the 
normal FTSECs and is more pronounced in metformin-
sensitive cells, it appears that biguanide treatment may 
specifically affect these mitochondrial shuttles in HGSC 
cells.
Aspartate and pyruvate supplementation rescue 
the anti-proliferative effects of metformin on cell 
growth
Given that metformin treatment results in a 
significant decrease in aspartate levels, we tested whether 
supplementation of cells with aspartate would rescue the 
anti-proliferative effects. We treated cells simultaneously 
with either control, aspartate (100 uM), metformin (10 
mM), or both aspartate and metformin for 72 h and 
assessed cell proliferation (Figure 9A). Treatment with 
aspartate alone had significant effects on the growth of 
all HGSC cell lines tested (Figure 9A). Aspartate had 
a minimal and non-significant effect on the growth of 
normal FTSEC cell lines (Figure 9A). Combinatorial 
treatment of all cell lines tested with aspartate and 
metformin resulted in a diminished effect of metformin, 
bringing cell viability close to control levels (Figure 9A). 
Therefore, aspartate supplementation diminishes the 
metformin effect as previously reported [15].
Previous studies have also shown that providing an 
alternative carbon source such as pyruvate can overcome 
the effects of metformin in cancer cell lines [15]. We 
also treated cells with either control, pyruvate (1 mM), 
metformin (10 mM), or both pyruvate and metformin for 
72 h and assessed cell proliferation. Strikingly, pyruvate 
treatment had a significantly positive effect on the growth of 
all normal FTSEC and HGSC cell lines (Figure 9B). Also, 
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Figure 6: Glucose deprivation sensitizes metformin resistant cell lines FUOV1 and OVCAR4 to metformin treatment. 
Cells were grown in standard glucose or limited glucose conditions were treated with vehicle or metformin (10 mM). Cell proliferation was 
assessed at 24 h, 72h, and 144 h. Proliferation is depicted relative to 24 h for each treatment. * denotes p-value < 0.01 relative to control. ** 
denotes p-value <0.01 relative to metformin in standard glucose media.
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Figure 7: The cancer-specific effects of biguanides on mitochondrial shuttle metabolites. (A) Metabolite analysis. Cells were 
treated with metformin (10 mM), phenformin (1 mM), or vehicle control for 24 hours and subjected to targeted mass spectrometry analysis. 
Metformin and phenformin treatments shown relative to untreated control. Yellow and blue heatmaps indicate increased or decreased 
levels relative to control, respectively. Data normalized by cell number. Complete metabolite changes located in Supplementary Figure 
2. (B) Quantification of G3P and aspartate fold changes induced by metformin treatment. Values listed as log2 fold change in metabolite 
abundance for metformin treated versus control normal FTSECs (blue), metformin-sensitive (red), and metformin-resistant (orange) cells. 
For G3P: *p-value < 0.05 vs normal cell lines by Games-Howell test, #p-value < 0.05 vs TYKNU, FUOV1, and OVCAR4 by Games-
Howell test, +p-value < 0.05 vs OVCAR4 by Games-Howell test. For aspartate: *p-value < 0.05 vs normal cell liens by Games-Howell test, 
#p-value < 0.05 vs FNE2 by Games-Howell test, +p-value < 0.05 vs OVCAR4 by Games-Howell test, &p-value < 0.05 vs OV90, FUOV1, 
and OVCAR4 by Games-Howell test, and %p-value < 0.05 vs OV90, OVCAR433, FUOV1, and OVCAR4 by Games-Howell test.
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Figure 8: Mitochondrial shuttles. (A) The glycerol-3-phosphate shuttle. cGPD = cytosolic glycerol-3-phosphate dehydrogenase, 
mGPD – mitochondrial glycerol-3-phosphate dehydrogenase. (B) The malate-aspartate shuttle. Numbers indicate the following enzymes 
and transporters: (1) Cytosolic aspartate aminotransferase (2) Malate dehydrogenase 1 (3) Malate-alpha-ketoglutarate antiporter (4) Malate 
dehydrogenase 2 (5) Mitochondrial aspartate aminotransferase (6) Glutamate-aspartate antiporter. Black and red dashed lines indicate the 
flow of α-ketoglutarate and glutamate between the cytosol and mitochondrial space.
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Figure 9: Asparate and pyruvate supplementation inhibits the effects of metformin on cell proliferation. Cells were 
seeded and after 24 h were treated with either control, metformin (10 mM) with or without (A) aspartate (100 uM) or (B) pyruvate (1 mM). 
Cell proliferation was assessed after an additional 72 h by Celltiter Glo. Proliferation is displayed relative to vehicle control. * denotes 
p-value < 0.01 relative to control. # denotes p-value < 0.01 relative to metformin treatment.
Oncotarget4057www.impactjournals.com/oncotarget
pyruvate significantly diminished the anti-proliferative 
effect of metformin on all cell lines, greater than the effect 
of aspartate (Figure 9B). This is in line with the report from 
Gui et al that pyruvate is a more powerful suppressant of 
metformin’s ability to inhibit cell growth than aspartate.
DISCUSSION
Multiple studies in different cancers have 
demonstrated that metformin and phenformin have a wide-
ranging impact on cancer metabolism [7, 21, 22]. In a Src-
inducible model of breast cancer, both biguanides were 
found to deplete TCA cycle intermediates as expected 
from Complex I inhibition [7]. Similar results were 
found using isolated mitochondria from breast cancer cell 
lines illustrating that biguanides indeed directly affect 
mitochondrial function [21]. Biguanide inhibition of TCA 
cycle activity was also found in NSCLC and colon cancer 
cell lines [22]. Interestingly, analysis of the effects of 
biguanides on breast cancer stem cells yielded a different 
metabolic profile; levels of all ribonucleotide and nucleotide 
triphosphates (NTPs) were significantly decreased, but no 
effects were seen on the TCA cycle [7]. In line with these 
results, we found that biguanides elicited similar effects on 
metabolites in the TCA cycle and/or NTPs in the HGSC 
cell lines tested (Supplementary Figure 3). In addition, this 
is the first study that characterizes the bioenergetics and 
metabolism of immortalized FTSECs, the purported cell 
of origin of HGSC [19]. Given that previous biguanide 
studies on ovarian cancer have not included FTSECs, 
we were able to identify metabolic effects induced by 
biguanides that were only seen in transformed HGSC cells. 
The most significant of these effects was the perturbation of 
metabolites involved with mitochondrial shuttles, the G3P 
and malate-aspartate shuttle (Figure 7A). Since NADH is 
unable to cross the mitochondrial membrane, shuttles exist 
to transfer electrons from cytosolic NADH to the electron 
transport chain (ETC) via the reduction of other molecules 
that can cross into the mitochondria. Mechanistically, the 
G3P shuttle functions in the following manner: Cytosolic 
G3P dehydrogenase 1 (cGPD) converts dihydroxyacetone 
phosphate (DHAP) to G3P by oxidizing NADH to NAD+. 
G3P is then converted back to DHAP by mitochondrial G3P 
dehydrogenase 2 (mGPD) to produce FADH2 that donates 
its electrons to the ETC (Figure 8A). The malate-aspartate 
shuttle utilizes malate and aspartate as electron carriers 
that are shuttled between the cytosol and mitochondria via 
exchange transporters (Figure 8B). These systems appear 
to be perturbed by biguanides in transformed HGSC cells 
as evidenced by elevated levels of G3P and depletion 
of aspartate. Interestingly, mGPD was found to be a 
direct target of biguanide inhibition in rats [25]. Whether 
biguanides inhibit the G3P and malate-aspartate shuttles 
directly in human cells has not been determined.
Recent evidence has shown that metformin 
accumulates within ovarian tumors and induces aspartate 
depletion [12]. This and other studies have posited that 
metformin prevents the mitochondria from adaptive 
nutrient utilization since metformin treatment can be 
rescued by providing alternative fuel sources such as 
pyruvate or increased amounts of glucose [12, 15, 16]. We 
have also confirmed the protective effect supplementation 
of glucose, aspartate, and pyruvate has against metformin 
(Figure 6 and 9). One caveat of our study is that cells 
were grown in RPMI media containing supraphysiologic 
levels of glucose (10 mM vs ~1-5mM) and higher levels 
of metformin (10 mM) than cells in vivo would be exposed 
to. However, the metabolomic changes upon metformin 
treatment seen in our in vitro data overlaps significantly 
with the changes seen in other in vivo studies, thereby 
suggesting translatability of our results [12, 15, 16]. Since 
biguanide treatment of most HGSC cell lines resulted in 
depleted nucleotides, increases in glycolysis (as shown 
by lactate and ECAR), and significant inhibition of ATP-
linked OCR, it follows that there is an increased need 
for glucose to provide the carbons required to replenish 
nucleotides and ATP via the pentose-phosphate shunt 
and glycolysis, respectively. Therefore, the ability of 
metformin to lower blood glucose levels and directly 
inhibit adaptive nutrient utilization in cancer cells imply 
a multi-faceted mechanism explaining the efficacy of this 
anti-tumor agent.
In summary, our study characterizes the metabolic 
and anti-proliferative effects of biguanides on HGSC cells 
and its cell of origin, FTSECs. Biguanides significantly 
inhibit the ETC and accumulate NADH in all cell lines 
implying that biguanides are also able to enter normal 
FTSEC cells and act on its direct target, Complex I. 
However, the anti-proliferative effects of metformin, 
but not phenformin, are HGSC cell specific and do not 
correlate with inhibition of mTOR activity. Metabolomic 
analysis revealed HGSC specific alterations in the levels 
of mitochondrial shuttle metabolites, aspartate and G3P, 
thereby illustrating that these processes are of particular 
importance, and possibly overactive in cancer cells. 
Alterations in these metabolites also correlate well with 
the anti-proliferative efficacy of metformin. The activity of 
these shuttles in HGSC cells versus normal FTSECs have 
not been described and are worth investigating. Further 
detailed analysis of the metabolic pathways perturbed in 
biguanide sensitive cells (i.e. deoxyuridine metabolism) 
as well as resistance mechanisms in metformin resistant 
cells may reveal additional metabolic therapeutic targets. 
Additionally, since this study identifies that metformin 
induces deleterious effects specifically in HGSC cells not 
seen in normal FTSECs and its low toxicity profile, its use 
as a preventative measure for HGSC should be taken into 
consideration.
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MATERIALS AND METHODS
Cell lines and reagents
FUOV1, OVCAR4, OV90, OVCAR433, and 
TYKNU were obtained as previously described [26]. 
FNE1 and FNE2 (TERT-immortalized normal FTSECs) 
were a kind gift from Dr. Tan Ince (University of Miami) 
[20]. Metformin, phenformin, and ultra-low attachment 
plates were obtained from Sigma-Aldrich. HGSC cells 
were grown in RPMI 1640 + 10% FBS + 1% penicillin/
streptomycin. FNE1 and FNE2 were grown in FOMI 
media [20] then switched to RPMI 1640 + 10% FBS + 1% 
penicllin/streptomycin 72 hours prior to assays.
Mitochondrial function and glycolysis
2x104 cells were plated into 24 well XF plates 
(Seahorse bioscience). Oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) were measured 
using an XF24 Extracellular Flux Analyzer (Seahorse 
Bioscience) in unbuffered DMEM assay medium 
supplemented with 1 mM pyruvate, 2 mM glutamine and 
11 mM glucose. OCR and ECAR were measured before 
and after the sequential addition of 0.5 μM oligomycin, 
0.5 μM FCCP and 1 μM of rotenone/myxothiazol. Values 
were normalized to protein concentration using a Bradford 
assay (Bio-Rad). Mitochondrial respiration was calculated 
as the difference between total and rotenone/myxothiazol 
rates. Maximal respiration was the response to FCCP. 
ATP-linked respiration was the oligomycin-sensitive 
respiration while uncoupled respiration was the difference 
between oligomycin and rotenone/myxothiazol rates.
Cell proliferation assay
1 × 103 cells/well were seeded in triplicate on a 
96-well plate and treated with metformin (1 mM or 10 
mM), phenformin (100μM or 1 mM), aspartate (100 uM), 
pyruvate (1 mM) or vehicle control (RPMI). To assess 
cellular viability, cells were subjected to the CelltiterGlo 
assay (Promega). Luminescence was read on a GloMax 
luminometer.
Spheroid formation assay
1 × 103 cells/well were seeded in triplicate in 
an ultra-low attachment 96-well plate and incubated 
overnight. Next day cells were treated with indicated 
doses of metformin, phenformin, or control for 72 hours. 
Viability was assessed by CelltiterGlo 3D assay.
Western blot analysis
Western blot was performed as previously described 
[27]. Briefly, cell lysates were collected in RIPA buffer 
supplemented with protease inhibitor cocktail and 
phosSTOP (Roche) and phosphatase inhibitor cocktail 
(Roche). 30 μg of pre-cleared cell lysate and 4x laemmli 
buffer were boiled for 10 minutes. Boiled lysates were 
run on a 4-20% gradient gel (BioRad) and transferred to a 
PVDF membrane. After blocking in 5% milk/TBS-T, blots 
were incubated overnight with primary antibody towards 
AMPK (Cell Signaling), phospho-AMPK (Cell Signaling), 
REDD1 (Protein Tech), S6K (Cell Signaling), phospho-
S6K (Cell Signaling), LKB1 (Santa Cruz) and β-actin 
(Sigma Aldrich). Blots were washed with TBS-T and 
incubated with secondary antibodies. Blots were scanned 
using the LiCOR Odyssey system.
qRT-PCR analysis
RNA extraction was performed using the RNeasy 
Mini Kit (Qiagen). RNA was reverse transcribed to 
cDNA using the Quantitect Reverse Trancription 
Kit (Qiagen). For qRT-PCR, 50 ng of cDNA was 
mixed with primers towards REDD1 (Forward 
5’-ACAGTTCTAGATGGAAGACC-3’, Reverse 
5’-ACAGTTCTAGATGGAAGACC-3’ or RPL32 
(Forward 5’-GTGCAACAAATCTTAC-TGTG, Reverse 
5’- CTGCCTACTCATTTTCTTCAC).
Metabolite extraction and analysis
Cells were cultured in 6-well plates with or without 
metformin (10 μM) or phenformin (1 μM) treatment for 
24 hours, and extracted at 80% confluency. Medium was 
aspirated, and each well was washed with 2ml saline 
(pH 7.5). Saline was aspirated, and cells were quenched 
with 500 μl of -75°C HPLC-grade methanol in each well. 
After adding 200 μl of HPLC-grade water to each well, 
cells were scraped with a cell lifter. All contents of each 
well was collected in a 1.7-ml microcentrifuge tube. 
Chloroform (500 μl at −20°C) was added to each tube and 
vortexed for 10 min at 4°C. Extracts were centrifuged at 
17,000 × g for 15 min at 4°C. The upper aqueous phase 
containing polar metabolites was collected in a separate 
microcentrifuge tube and evaporated under a stream 
of nitrogen. Metabolites were resuspended in 100 μl of 
HPLC-grade water immediately before analysis by mass 
spectrometry. The metabolites were analyzed using a 
Waters Xevo TQ-S mass spectrometer coupled to an 
H-Class UPLC system. Metabolites were separated by 
polarity using a Supelco Ascentis Express C18 column (2.7 
μm particle size, 5 cm × 2.1 mm). LC parameters are as 
follows: autosampler temperature, 5 °C; injection volume, 
5 μl; column temperature, 50 °C; flow rate over 11 min: t = 
0, 0.4 ml min−1; t = 2, 0.3 ml min−1; t = 3, 0.25 ml min−1; t 
= 5, 0.15 ml min−1; t = 9, 0.4 ml min−1; t = 11, 0.4 ml min−1. 
The LC solvents were solvent A: 10 mM tributylamine 
and 15 mM acetic acid in 97:3 water:methanol (pH 4.95); 
and solvent B: methanol. Elution from the column was 
performed over 11 min with the following gradient: t = 
0, 0% B; t = 1, 0% B; t = 2, 20% B; t = 3, 20% B; t = 5, 
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55% B; t = 8, 95% B; t = 8.5, 95% B, t = 9, 0% B; t = 11, 
0% B. Mass spectra were acquired using negative-mode 
electrospray ionization operating in multiple reaction 
monitoring (MRM) mode. The capillary voltage was 3,000 
V, and cone voltage was 50 V. Nitrogen was used as cone 
gas and desolvation gas, with flow rates of 150 l h−1 and 
600 l h−1, respectively. The source temperature was 150 
°C, and desolvation temperature was 500 °C. Argon was 
used as collision gas at a manifold pressure of 4.3 × 10-3 
mbar. Collision energies and source cone potentials were 
optimized for each transition using Waters QuanOptimize 
software. Data analysis was performed using MAVEN 
[28, 29]. Metabolite measurements were normalized by 
cell counts.
Abbreviations
ATP = adenosine triphosphate; cGPD = cytosolic 
glycerol-3-phosphate dehydrogenase 1; CTP = cytidine 
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tube epithelium; FTSECs = fallopian tube secretory 
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phosphate dehydrogenase 2; OCR = oxygen consumption 
rate; UTP = uridine triphosphate.
Author contributions
P.J.P.A. initiated and oversaw the entire study 
design and execution. M.H. and P.J.P.A performed the 
proliferation assays and helped with the bioenergetic and 
metabolomics experiments. L.V. and K.R. performed 
and helped interpret the bioenergetic experiments. B.Y.K 
helped with data analysis and interpretation. M.O. and 
S.Y.L. performed and helped interpret the metabolomics 
data. All authors helped with manuscription preparation.
ACKNOWLEDGMENTS AND FUNDING
We would like to thank members of the Women’s 
Cancer Program at Cedars-Sinai Medical Center for 
their thoughtful input and insight in completion of this 
manuscript. We would also like to thank Dr. Tan Ince 
(U. of Miami) for providing the normal immortalized 
FTSEC cell lines, FNE1 and FNE2. This work was 
supported by a Program Project Development Grant 
from the Ovarian Cancer Research Fund Alliance [Co-
Evolution of Epithelial Ovarian cancer and Tumor Stroma, 
373356]. The work of K.R. is supported by the National 
Center for Research Resources Grant S10RR026744. 
The work of S.Y.L. and M.O. is supported by Office of 
the Assistant Secretary of Defense for Health Affairs, 
through the Breast Cancer Research Program, under 
Award No. W81XWH-15-1-0453. S.Y.L. is also supported 
by 2016 AACR-Incyte Corporation NextGen Grant for 
Transformative Cancer Research, Grant Number 16-20-
46-LUNT.
CONFLICTS OF INTEREST
Authors declare no conflicts of interest.
REFERENCES
1. Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, 
Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, 
Brenton JD, Chiappinelli KB, Martins FC, et al. Rethinking 
ovarian cancer II: reducing mortality from high-grade 
serous ovarian cancer. Nat Rev Cancer. 2015; 15:668–79. 
https://doi.org/10.1038/nrc4019.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. 
CA Cancer J Clin. 2015; 65:5–29. https://doi.org/10.3322/
caac.21254.
3. Nestler JE. Metformin in the treatment of infertility in 
polycystic ovarian syndrome: an alternative perspective. 
Fertil Steril. 2008; 90:14–6. https://doi.org/10.1016/j.
fertnstert.2008.04.073.
4. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, 
Morris AD. Metformin and reduced risk of cancer in 
diabetic patients. BMJ. 2005; 330:1304–5. https://doi.
org/10.1136/bmj.38415.708634.F7.
5. Gong Z, Aragaki AK, Chlebowski RT, Manson JE, Rohan 
TE, Chen C, Vitolins MZ, Tinker LF, LeBlanc ES, Kuller 
LH, Hou L, LaMonte MJ, Luo J, et al. Diabetes, metformin 
and incidence of and death from invasive cancer in 
postmenopausal women: results from the women’s health 
initiative. Int J Cancer. 2016; 138:1915–27. https://doi.
org/10.1002/ijc.29944.
6. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, 
Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, 
Shaw RJ. LKB1 inactivation dictates therapeutic response 
of non-small cell lung cancer to the metabolism drug 
phenformin. Cancer Cell. 2013; 23:143–58. https://doi.
org/10.1016/j.ccr.2012.12.008.
7. Janzer A, German NJ, Gonzalez-Herrera KN, Asara JM, 
Haigis MC, Struhl K. Metformin and phenformin deplete 
tricarboxylic acid cycle and glycolytic intermediates 
during cell transformation and ntps in cancer stem cells. 
Proc Natl Acad Sci U S A. 2014; 111:10574–9. https://doi.
org/10.1073/pnas.1409844111.
8. Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, 
Reynolds RK, Buckanovich RJ. Metformin targets ovarian 
cancer stem cells in vitro and in vivo. Gynecol Oncol. 2012; 
127:390–7. https://doi.org/10.1016/j.ygyno.2012.07.115.
9. Rena G, Pearson ER, Sakamoto K. Molecular 
mechanism of action of metformin: old or new insights? 
Diabetologia. 2013; 56:1898–906. https://doi.org/10.1007/
s00125-013-2991-0.
Oncotarget4060www.impactjournals.com/oncotarget
10. Pernicova I, Korbonits M. Metformin--mode of action 
and clinical implications for diabetes and cancer. Nat Rev 
Endocrinol. 2014; 10:143–56. https://doi.org/10.1038/
nrendo.2013.256.
11. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes 
S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu 
GM, Budigner GS, Chandel NS. Metformin inhibits 
mitochondrial complex i of cancer cells to reduce 
tumorigenesis. Elife. 2014; 3:e02242. https://doi.
org/10.7554/eLife.02242.
12. Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale 
JW. Metformin targets central carbon metabolism and 
reveals mitochondrial requirements in human cancers. 
Cell Metab. 2016; 24:728–39. https://doi.org/10.1016/j.
cmet.2016.09.005.
13. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le 
Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi 
S, Bost F. Metformin, independent of ampk, induces mTOR 
inhibition and cell-cycle arrest through REDD1. Cancer 
Res. 2011; 71:4366–72. https://doi.org/10.1158/0008-5472.
CAN-10-1769.
14. Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh 
A, Rodrigues Hoffman A, Safe S. Mechanism of 
metformin-dependent inhibition of mammalian target of 
rapamycin (mTOR) and ras activity in pancreatic cancer: 
role of specificity protein (Sp) transcription factors. J Biol 
Chem. 2014; 289:27692–701. https://doi.org/10.1074/jbc.
M114.592576.
15. Gui DY, Sullivan LB, Luengo A, Hosios AM, Bush LN, 
Gitego N, Davidson SM, Freinkman E, Thomas CJ, 
Vander Heiden MG. Environment dictates dependence 
on mitochondrial complex I for NAD+ and aspartate 
production and determines cancer cell sensitivity to 
metformin. Cell Metab. 2016; 24:716–27. https://doi.
org/10.1016/j.cmet.2016.09.006.
16. Litchfield LM, Mukherjee A, Eckert MA, Johnson A, 
Mills KA, Pan S, Shridhar V, Lengyel E, Romero IL. 
Hyperglycemia-induced metabolic compensation inhibits 
metformin sensitivity in ovarian cancer. Oncotarget. 2015; 
6:23548–60. https://doi.org/10.18632/oncotarget.4556.
17. Febbraro T, Lengyel E, Romero IL. Old drug, new trick: 
repurposing metformin for gynecologic cancers? Gynecol 
Oncol. 2014; 135:614–21. https://doi.org/10.1016/j.
ygyno.2014.10.011.
18. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. 
Evaluating cell lines as tumour models by comparison of 
genomic profiles. Nat Commun. 2013; 4:2126. https://doi.
org/10.1038/ncomms3126.
19. Perets R, Drapkin R. It’s totally tubular....Riding the new 
wave of ovarian cancer research. Cancer Res. 2016; 76:10–
7. https://doi.org/10.1158/0008-5472.CAN-15-1382.
20. Merritt MA, Bentink S, Schwede M, Iwanicki MP, 
Quackenbush J, Woo T, Agoston ES, Reinhardt F, Crum 
CP, Berkowitz RS, Mok SC, Witt AE, Jones MA, et al. 
Gene expression signature of normal cell-of-origin predicts 
ovarian tumor outcomes. PLoS One. 2013; 8:e80314. 
https://doi.org/10.1371/journal.pone.0080314.
21. Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. 
Metformin directly acts on mitochondria to alter cellular 
bioenergetics. Cancer Metab. 2014; 2:12. https://doi.
org/10.1186/2049-3002-2-12.
22. Griss T, Vincent EE, Egnatchik R, Chen J, Ma EH, Faubert 
B, Viollet B, DeBerardinis RJ, Jones RG. Metformin 
antagonizes cancer cell proliferation by suppressing 
mitochondrial-dependent biosynthesis. PLoS Biol. 2015; 
13:e1002309. https://doi.org/10.1371/journal.pbio.1002309.
23. Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, 
Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, McPherson 
C, Warnick RE, Kendler A, et al. Discrete mechanisms 
of mTOR and cell cycle regulation by AMPK agonists 
independent of AMPK. Proc Natl Acad Sci U S A. 2014; 
111:E435–44. https://doi.org/10.1073/pnas.1311121111.
24. Menzies KJ, Zhang H, Katsyuba E, Auwerx J. Protein 
acetylation in metabolism - metabolites and cofactors. Nat 
Rev Endocrinol. 2016; 12:43–60. https://doi.org/10.1038/
nrendo.2015.181.
25. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock 
DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, 
MacDonald MJ, Jurczak MJ, Camporez JP, Lee HY, et 
al. Metformin suppresses gluconeogenesis by inhibiting 
mitochondrial glycerophosphate dehydrogenase. Nature. 
2014; 510:542–6. https://doi.org/10.1038/nature13270.
26. Taylor Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, 
Mizuno T, Greenberg D, Allen JR, Spurka L, Funari V, 
Spiteri E, Wang Q, Orsulic S, Walsh C, et al. Cyclin E1 
and RTK/RAS signaling drive CDK inhibitor resistance via 
activation of E2F and ETS. Oncotarget. 2015; 6:696–714. 
https://doi.org/10.18632/oncotarget.2673.
27. Aspuria PJ, Lunt SY, Varemo L, Vergnes L, Gozo M, 
Beach JA, Salumbides B, Reue K, Wiedemeyer WR, 
Nielsen J, Karlan BY, Orsulic S. Succinate dehydrogenase 
inhibition leads to epithelial-mesenchymal transition and 
reprogrammed carbon metabolism. Cancer Metab. 2014; 
2:21. https://doi.org/10.1186/2049-3002-2-21.
28. Clasquin MF, Melamud E, Rabinowitz JD. (2012). LC-MS 
data processing with maven: a metabolomic analysis and 
visualization engine. current protocols in bioinformatics: 
John Wiley & Sons, Inc.
29. Melamud E, Vastag L, Rabinowitz JD. Metabolomic 
analysis and visualization engine for LC−MS data. 
Anal Chem. 2010; 82:9818–26. https://doi.org/10.1021/
ac1021166.
